Based on studies in mice and rats, miR-132 reduces both mRNA and protein levels of MECP2. miR-132 is therefore expected to function in the context of the endonucleolytic RISC, and possibly also non-endonucleolytic RISC. MicroRNA miR-132 is complementary to the 3'UTR of long MECP2 transcripts (>10 kb), which are predominantly expressed in the brain (Klein et al. 2007, Su et al. 2015). Based on sequence similarity, human MECP2 mRNA is also predicted to be a miR-132 target.